This website is managed by Ultima Markets’ international entities, and it’s important to emphasise that they are not subject to regulation by the FCA in the UK. Therefore, you must understand that you will not have the FCA’s protection when investing through this website – for example:
You will not be guaranteed Negative Balance Protection
You will not be protected by FCA’s leverage restrictions
You will not have the right to settle disputes via the Financial Ombudsman Service (FOS)
You will not be protected by Financial Services Compensation Scheme (FSCS)
Any monies deposited will not be afforded the protection required under the FCA Client Assets Sourcebook. The level of protection for your funds will be determined by the regulations of the relevant local regulator.
Note: UK clients are kindly invited to visit https://www.ultima-markets.co.uk/. Ultima Markets UK expects to begin onboarding UK clients in accordance with FCA regulatory requirements in 2026.
If you would like to proceed and visit this website, you acknowledge and confirm the following:
1.The website is owned by Ultima Markets’ international entities and not by Ultima Markets UK Ltd, which is regulated by the FCA.
2.Ultima Markets Limited, or any of the Ultima Markets international entities, are neither based in the UK nor licensed by the FCA.
3.You are accessing the website at your own initiative and have not been solicited by Ultima Markets Limited in any way.
4.Investing through this website does not grant you the protections provided by the FCA.
5.Should you choose to invest through this website or with any of the international Ultima Markets entities, you will be subject to the rules and regulations of the relevant international regulatory authorities, not the FCA.
Ultima Markets wants to make it clear that we are duly licensed and authorised to offer the services and financial derivative products listed on our website. Individuals accessing this website and registering a trading account do so entirely of their own volition and without prior solicitation.
By confirming your decision to proceed with entering the website, you hereby affirm that this decision was solely initiated by you, and no solicitation has been made by any Ultima Markets entity.
Biotechnology is one of the most dynamic sectors in the financial markets, fueled by innovations in gene therapy, precision medicine, diagnostics, and industrial biotech. If you want exposure to this fast-evolving industry without picking individual stocks, knowing which are the top biotech ETFs are key. These ETFs provide access to both established leaders and high-potential innovators, allowing investors to balance growth opportunities and risk.
In 2026, biotech ETFs have been gaining attention due to renewed M&A activity, positive clinical trial outcomes, and selective regulatory easing. However, each ETF differs in structure, holdings, and volatility, so choosing the right one is crucial.
Why Biotech ETFs Deserve A Place in Your Portfolio
Biotech stocks are inherently event-driven. Clinical trial results, regulatory approvals, and mergers or acquisitions can create rapid price swings. ETFs allow investors to participate in innovation while spreading single-stock risk, making them an efficient way to access the sector.
Investing in top biotech ETFs gives you exposure to both large-cap, stable companies and smaller, high-potential firms that could benefit from breakthrough discoveries or market-moving news. Understanding the difference between these fund types is key to matching your investment strategy with your risk tolerance.
Leading Biotech ETFs in 2026
Here’s a breakdown of top biotech ETFs that investors are watching in 2026:
1. iShares Nasdaq US Biotechnology UCITS ETF (IE00BYXG2H39)
This ETF offers broad, diversified exposure to large-cap biotech names, making it suitable as a core long-term holding. Its top-heavy structure means it moves more steadily, reacting less dramatically to single-event news.
Focus: Similar broad Nasdaq exposure with slightly smaller fund size
Performance: 1-year +9.15%, 3-year +13.01%
Comparable to iShares, this fund is suitable for core sector exposure, offering a balance of growth and stability.
3. Global X Genomics & Biotechnology UCITS ETF (IE00BM8R0N95)
Fund size: €15M
TER: 0.50% p.a.
Structure: Accumulating, full replication, Ireland
Focus: Small/mid-cap genomics and biotech innovators
Performance: 1-year +3.27%, 3-year -25.7%
GNOM provides a high-risk, high-reward profile. With only 50 holdings, a single major discovery or acquisition can dramatically move the ETF’s price, making it attractive for tactical investors.
Structure: Accumulating, full replication, Ireland
Focus: Innovative biotech companies
Performance: 1-year +4.88%, 3-year -16.96%
This fund blends small/mid-cap exposure with thematic focus on bio-revolution technologies, offering potential for outsized gains in breakthrough sectors.
5. Alps Medical Breakthroughs ETF (SBIO)
Fund size: ~$100M
Holdings: ~100 stocks, top 10 <30%
Performance: Up 31% since April 2025
Focus: Event-driven small-cap biotech
SBIO is highly sensitive to clinical and M&A catalysts, providing an opportunity for aggressive traders seeking rapid growth in the biotech space.
2026 Market Trends and ETF Performance
Biotech ETFs have shown distinct performance patterns this year. Smaller, thematic ETFs like GNOM and SBIO have rebounded sharply due to promising scientific discoveries and mergers & acquisitions, while larger ETFs like iShares and Invesco have moved more steadily.
This contrast highlights how fund size, holdings, and sector dynamics shape returns. Investors can use this insight to select ETFs that match their risk tolerance and investment objectives.
Comparing Large-Cap vs Small/Mid-Cap ETFs
While all biotech ETFs provide exposure to the sector, not all funds behave the same. Performance, volatility, and growth potential can differ significantly depending on whether the ETF focuses on large-cap, established biotech companies or smaller, high-potential innovators. To better understand these differences, let’s compare how large-cap and small/mid-cap biotech ETFs have performed in 2026.
ETF
Focus
Approx. 1-Yr Return (as of early 2026)
Notes
iShares Nasdaq US Biotechnology UCITS ETF
Large-cap biotech
Around mid-teens to high teens annual return (est.)
Strong performance driven by smaller biotech stocks earlier in 2025/2026, showing higher volatility and episodic upside.
Global X Genomics & Biotechnology ETF (GNOM)
Genomics/thematic
Traded up with positive momentum YTD
GNOM’s price range increased significantly into 2026; performance shows a meaningful recovery compared with prior years.
WisdomTree BioRevolution Fund (WDNA)
Bio-innovation thematic
~20–23%+ 1-yr performance
Thematic, growth-oriented biotech exposure benefiting from broader life sciences momentum.
Key takeaway:
Large-cap diversified ETFs (like the iShares Nasdaq US Biotech UCITS ETF) have delivered steady, broad exposure tied to established biotech companies.
Small and thematic ETFs (SBIO, GNOM, WDNA) show higher variability but stronger episodic returns linked to breakthroughs, trial outcomes, or sector rotations.
Across the board, 2026 is reflecting continued investor appetite for biotech innovation, particularly where genomics, therapeutics, and tools platforms exhibit catalysts.
Choosing the Right Biotech ETF
Define your horizon:
Short-term trades: Small/mid-cap or event-driven ETFs (GNOM, SBIO)
Higher volatility = potential for outsized gains and losses
Lower volatility = steadier returns
Check costs and structure:
TER ranges from 0.35%–0.50% p.a.
Accumulating vs distributing, replication method, and domicile affect efficiency and tax considerations.
Monitor catalysts:
Regulatory changes, M&A activity, and clinical trial results can drive performance, especially in smaller ETFs.
Final Thoughts
Biotech ETFs offer a powerful, diversified way to invest in medical innovation. In 2026, small-cap and thematic ETFs have delivered sharp gains, while large-cap ETFs provided steady, stable returns. By understanding fund size, holdings, replication methods, and catalyst sensitivity, investors can choose the top biotech ETFs that best align with their goals and risk profile.
Whether your goal is steady growth or tactical exposure to breakthroughs, top biotech ETFs in 2026 provide multiple pathways to participate in the next wave of healthcare innovation.
Disclaimer: This content is provided for informational purposes only and does not constitute, and should not be construed as, financial, investment, or other professional advice. No statement or opinion contained here in should be considered a recommendation by Ultima Markets or the author regarding any specific investment product, strategy, or transaction. Readers are advised not to rely solely on this material when making investment decisions and should seek independent advice where appropriate.
Thank you for visiting the Ultima Markets website. Please note that this website is intended for individuals residing in jurisdictions where accessing is permitted by law. Ultima and its affiliated entities do not operate in your home jurisdictions.
By clicking on ''Acknowledge'', you confirm that you are entering this website solely based on your initiative and not as a result of any specific marketing outreach. You wish to obtain information from this website based on reverse solicitation principles, in accordance with the applicable laws of your home jurisdiction.
